HOYA Vision Care Australia & New Zealand launches MiYOSMART Sun Spectacle Lenses, Combining Protection From Intense Sunlight With Myopia Management
Sydney, Australia – Today, Hoya Vision Care, a leader in optical technology innovation, announced the launch of the MiYOSMART sun range. The photochromic spectacle lenses, MiYOSMART Chameleon; and polarised spectacle lenses, MiYOSMART Sunbird, were developed to slow down myopia progression in children using D.I.M.S. Technology, while providing protection from intense sunlight.1-4 These two new products, along with the MiYOSMART clear spectacle lenses which launched in 2018, give children the freedom to comfortably take part in the activities they enjoy indoors and outdoors without compromising their eyesight.
MiYOSMART Chameleon and MiYOSMART Sunbird both provide protection from intense sunlight, while simultaneously correcting the myopic refractive error and slowing myopia progression.1-4 The new spectacle lenses utilise the same D.I.M.S. Technology used in the award-winning5,6 and non-invasive MiYOSMART clear spectacle lenses, shown to slow myopia progression by 60% in children aged 8 to 13.7 Due to the HOYA photochromic lens technology, MiYOSMART Chameleon is an all-in-one solution to myopia management and protected outdoor activity.2-4 It rapidly adapts to the level of sunlight and fades back to clear indoors quickly.3 Meanwhile, MiYOSMART Sunbird is the ideal addition to MiYOSMART clear spectacle lenses, for extra protection from intense sunlight and glare.1,8 It also offers vibrant colours and rich contrast in bright light, allowing children to fully experience the beauty of outdoors.9
“Children’s vision is worth protecting. By acting today, we give them more opportunity tomorrow”, said Frederiek Ysebaert, Managing Director of the Pediatric Care Business Unit at HOYA Vision Care. “With the launch of MiYOSMART sun spectacle lenses, inspired by our discussions with Eye Care Professionals, we can enable children across the world to spend more time outdoors, while protecting their eyes from intense sunlight, maximising the benefits of D.I.M.S. Technology on myopia progression.”
Alongside the launch of the MiYOSMART sun range, Hoya Vision Care will launch “protect how they see the world”, a dedicated global campaign to raise awareness of the importance of outdoor time and sun protection in children. Spending time outdoors may slow down myopia progression in children,10,11 and as such it is the most common recommended behavioural management for myopia given by Eye Care Professionals.12 However, as the majority of lifetime sun exposure occurs under the age of 21, it is necessary to prevent long-term eye damage to children’s eyes with effective and reliable sun protection.8,13,14 This is particularly important for myopic children using atropine eyedrops for myopia management, and those that are light-sensitive.15-17
Since 2018, 2 million patients in over 30 countries have benefited from wearing MiYOSMART spectacle lenses.18 With the launch of MiYOSMART Chameleon and MiYOSMART Sunbird, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.
Product Disclaimer: MiYOSMART spectacle lenses have not been approved for use in the management of Myopia in all countries, including the U.S., and are not currently available for sale in all countries, including the U.S.
References
1. HOYA data on file. Transmission, traffic light recognition, and UV blocking test for MiYOSMART clear and polarized lenses. 02/2023. Tests were conducted at room temperature (23°C).
2. HOYA data on file. PSF test on MiYOSMART clear and sun spectacle lenses. 06/2022.
3. HOYA data on file. Lens performance validation test for MiYOSMART photochromic lenses – activation and deactivation. 02/2023. Tests were conducted at room temperature (23°C).
4. HOYA data on file. Transmission, traffic light recognition, and UV blocking test for MiYOSMART clear and photochromic lenses. 02/2023. Tests were conducted at room temperature (23°C).
5. Winners of the exhibition’s grand prix. Inventions Geneva. N.D. Available from: https://inventions-geneva.ch/en/winners/ (Last accessed 20/02/2023)
6. Winners 2020. Silmo Paris. 2020. https://en.silmoparis.com/SILMO-d-OR/SILMO-d-Or-Awards/2020-Winners# (Last accessed 20/02/2023).
7. Lam CSY, Tang WC, Tse DY, et al. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. Br J Ophthalmol. 2020;104(3):363-368.
8. WSPOS. Sunlight Exposure & Children’s Eyes Consensus Statement. 2016. Available at: https://www.wspos.org/wspos-sunlight-exposure-childrens-eyes-consensus-statement/ (Last accessed 20/02/2023)
9. Quintana MS, Langa A, del Moral-Martinez I, et al. Polarized Filters Enhance Contrast Sensitivity When Glare Is Produced On A Flat Surface Under Photopic Conditions. Invest Ophthalmol Vis Sci. 2006;47(13):1225.
10. Ho CL, Wu WF, Liou YM. Dose-Response Relationship of Outdoor Exposure and Myopia Indicators: A Systematic Review and Meta-Analysis of Various Research Methods. Int J Environ Res Public Health. 2019;16(14):2595.
11. Jonas JB, Ang M, Cho P, et al. IMI prevention of myopia and its progression. Invest Ophthalmol Vis Sci. 2021;62(5):6.
12. WSPOS. Myopia Survey Data. November 2022. Presented as part of WSPOS Symposium: Comprehensive Update on Myopia Management.19-20 November 2022. Available from: http://forum.wspos.org/symposium-part-1-comprehensive-update-on-myopia-management-2
13. Artigas JM, Felipe A, Navea A, Fandiño A, Artigas C. Spectral transmission of the human crystalline lens in adult and elderly persons: color and total transmission of visible light. Invest Ophthalmol Vis Sci. 2012;53(7):4076-4084.
14. Prevent Blindness. Children’s Eyes are More Susceptible to Long-Term Damage from UV Rays. 2011. Available at: https://preventblindness.org/childrens-eyes-are-more-susceptible-to-long-term-damage-from-uv-rays/ (Last accessed 20/02/2023)
15. Li FF, Yam JC. Low-Concentration Atropine Eye Drops for Myopia Progression. Asia Pac J Ophthalmol (Phila). 2019;8(5):360-365.
16. Gong Q, Janowski M, Luo M, et al. Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis. JAMA Ophthalmol. 2017;135(6):624-630.
17. Wu PC, Chuang MN, Choi J, et al. Update in myopia and treatment strategy of atropine use in myopia control. Eye (Lond). 2019;33(1):3-13.
18. Based on number of MiYOSMART lenses sold as per HOYA sales data on file as of June 2022.
About HOYA Vision Care
For over 60 years, HOYA Vision Care has been a passionate and global leader in optical technology innovation. As a manufacturer of high quality, high performing eyeglass lenses, HOYA continuously aims to bring the best possible vision care solutions to Eye Care Professionals and their patients around the world. The company supplies lenses in 110 countries with a network of over 17,000 employees and 43 laboratories around the globe.
About HOYA
Founded in 1941 in Tokyo, Japan, HOYA Corporation is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products. HOYA’s divisions and business units research and develop products utilized in the healthcare and information technology fields. In the healthcare field, we provide medical device products such as eyeglasses, medical endoscopes, contact and intraocular lenses, orthopedic implants, surgical/therapeutic devices and medical device reprocessing and disinfection solutions. In the information technology field, we provide products such as optical lenses, photomasks and blanks used in the manufacturing process for semiconductor and LCD/OLED devices, text to speech, human resources and other software solutions and critical components for the mass memory and cloud storage industries. With over 150 offices and subsidiaries worldwide, HOYA currently employs a multinational workforce of 37,000 people.
For further information (not for publication) contact:
Ulli Hentschel
HOYA ANZ Training & Development Manager
E: ulli.hentschel@hoya.com
M: 0498 016 278